Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Single Arm, Single Center Phase II Study of Adriamycin and Ifosfamide Combined With Sintilimab in the Treatment of Advanced or Unresectable Soft Tissue Sarcoma

X
Trial Profile

An Open, Single Arm, Single Center Phase II Study of Adriamycin and Ifosfamide Combined With Sintilimab in the Treatment of Advanced or Unresectable Soft Tissue Sarcoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Sintilimab (Primary) ; Vincristine (Primary)
  • Indications Alveolar soft part sarcoma; Chondrosarcoma; Clear cell sarcoma; Dermatofibrosarcoma; Gastrointestinal stromal tumours; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Osteosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour; Synovial sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Dec 2023 Planned number of patients changed from 69 to 176.
    • 25 Dec 2023 Planned End Date changed from 30 Jul 2024 to 30 Jul 2026.
    • 25 Dec 2023 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top